BR112022001710A2 - Moléculas mhc de classe ii e métodos de uso das mesmas - Google Patents

Moléculas mhc de classe ii e métodos de uso das mesmas

Info

Publication number
BR112022001710A2
BR112022001710A2 BR112022001710A BR112022001710A BR112022001710A2 BR 112022001710 A2 BR112022001710 A2 BR 112022001710A2 BR 112022001710 A BR112022001710 A BR 112022001710A BR 112022001710 A BR112022001710 A BR 112022001710A BR 112022001710 A2 BR112022001710 A2 BR 112022001710A2
Authority
BR
Brazil
Prior art keywords
class
amino acid
methods
molecules
hla
Prior art date
Application number
BR112022001710A
Other languages
English (en)
Inventor
Kenji Sugata
Naoto Hirano
Original Assignee
Univ Health Network
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Health Network filed Critical Univ Health Network
Publication of BR112022001710A2 publication Critical patent/BR112022001710A2/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70514—CD4
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56977—HLA or MHC typing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6878—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids in eptitope analysis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/73—Fusion polypeptide containing domain for protein-protein interaction containing coiled-coiled motif (leucine zippers)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70539—MHC-molecules, e.g. HLA-molecules

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)

Abstract

moléculas mhc classe ii e métodos de uso das mesmas. a presente invenção refere-se a moléculas hla de classe ii tendo uma afinidade maior para cd4 do que as moléculas hla de classe ii que ocorrem naturalmente. em certos aspectos, a molécula hla de classe ii compreende uma cadeia dq beta tendo (i) um aminoácido que não leucina em uma posição correspondente ao resíduo de aminoácido 114 da seq id no: 1, (ii) um aminoácido que não a valina em uma posição correspondente ao resíduo de aminoácido 143 da seq id no: 1, (iii) ou ambos (i) e (ii). certos aspectos da presente invenção referem-se a moléculas de ácido nucleico que codificam as moléculas hla de classe ii, vetores compreendendo a molécula de ácido nucleico, células que compreendem as mesmas, e métodos de uso das mesmas.
BR112022001710A 2019-07-30 2020-07-29 Moléculas mhc de classe ii e métodos de uso das mesmas BR112022001710A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962880501P 2019-07-30 2019-07-30
US202063029114P 2020-05-22 2020-05-22
PCT/IB2020/057173 WO2021019473A1 (en) 2019-07-30 2020-07-29 Mhc class ii molecules and methods of use thereof

Publications (1)

Publication Number Publication Date
BR112022001710A2 true BR112022001710A2 (pt) 2022-06-21

Family

ID=74228599

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022001710A BR112022001710A2 (pt) 2019-07-30 2020-07-29 Moléculas mhc de classe ii e métodos de uso das mesmas

Country Status (12)

Country Link
US (1) US20220275051A1 (pt)
EP (1) EP4004034A4 (pt)
JP (1) JP2022542447A (pt)
KR (1) KR20220052943A (pt)
CN (1) CN114450302A (pt)
AU (1) AU2020322246A1 (pt)
BR (1) BR112022001710A2 (pt)
CA (1) CA3146292A1 (pt)
IL (1) IL290223A (pt)
MX (1) MX2022001210A (pt)
TW (1) TW202116797A (pt)
WO (1) WO2021019473A1 (pt)

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100364611C (zh) * 1996-11-13 2008-01-30 明治乳业株式会社 肽基免疫治疗剂
AU2002240057A1 (en) * 2001-01-24 2002-08-06 President And Fellows Of Harvard College Therapeutic peptides for demyelinating conditions
GB0107628D0 (en) * 2001-03-27 2001-05-16 Avidex Ltd Substances
EP1403283A4 (en) * 2001-06-12 2006-05-10 Greenpeptide Co Ltd TUMOR ANTIGENS
EP1696027A4 (en) * 2003-11-05 2008-05-14 Int Inst Cancer Immunology Inc ANTIGEN PEPTIDE BINDING TO ORIGINAL HLA-DR WT1
CN101001868A (zh) * 2004-06-17 2007-07-18 曼康公司 表位类似物
US20060084116A1 (en) * 2004-09-13 2006-04-20 Xencor, Inc. Analysis of MHC-peptide binding interactions
US20060228758A1 (en) * 2004-09-13 2006-10-12 Xencor, Inc. Analysis of MHC-peptide binding interactions
WO2008109075A2 (en) * 2007-03-05 2008-09-12 Bristol-Myers Squibb Company Biomarkers and methods for determining sensitivity to ctla-4 antagonists
WO2016135363A1 (es) * 2015-02-23 2016-09-01 Servicio Andaluz De Salud Método de obtención de datos útiles para predecir o pronosticar la transmisión vertical, la cronificación y/o el aclaramiento del virus de la hepatitis c
US11396536B2 (en) * 2016-04-27 2022-07-26 University Health Network Peptide-HLA complexes and methods of producing same
CN111712254A (zh) * 2017-12-23 2020-09-25 鲁比厄斯治疗法股份有限公司 人工抗原呈递细胞和使用方法

Also Published As

Publication number Publication date
EP4004034A1 (en) 2022-06-01
IL290223A (en) 2022-03-01
MX2022001210A (es) 2022-05-03
KR20220052943A (ko) 2022-04-28
US20220275051A1 (en) 2022-09-01
TW202116797A (zh) 2021-05-01
CA3146292A1 (en) 2021-02-04
AU2020322246A1 (en) 2022-03-03
WO2021019473A1 (en) 2021-02-04
CN114450302A (zh) 2022-05-06
JP2022542447A (ja) 2022-10-03
EP4004034A4 (en) 2023-11-15

Similar Documents

Publication Publication Date Title
BR112018000477A2 (pt) proteína de ligação de imunoglobulina não natural, composição, uso da proteína de ligação de ig não natural, método de purificação de afinidade de imunoglobulinas, método de geração de uma proteína de ligação de imunoglobulina não natural, molécula de ácido nucleico, vetor, célula hospedeira ou um hospedeiro não humano, e método para a produção de uma proteína de ligação de imunoglobulina não natural
CY1122576T1 (el) Ανθρωπινα αντισωματα που δεσμευουν το γονιδιο-3 ενεργοποιησης λεμφοκυτταρων (leg-3), και χρησεις εξ' αυτων
WO2022109339A8 (en) Use of dextramer in single cell analysis
AR060583A1 (es) Anticuerpo de c- kit humanizado
BRPI0620946A8 (pt) anticorpo il-23p19 isolado, composição, método in vitro, artigo de fabricação, molécula e vetor de ácido nucleico, célula hospedeira procariótica
BR112012017124B8 (pt) método para produzir e para purificar um multímero polipeptídico
BRPI0515649B8 (pt) Processo para preparação de composições de anticorpo monoclonal altamente concentradas
BRPI0612273C1 (pt) anticorpo de ligação a il-1 beta ou fragmento de ligação a il-1 beta do mesmo, ácido nucleico, vetor, e, composição
AR083295A1 (es) Metodo para activar celulas t auxiliares
WO2020123425A3 (en) Antibodies modified for transglutaminase conjugation, conjugates thereof, and methods and uses
BR112021018734A2 (pt) Receptores de células t e métodos de uso destes
BR112012011598A2 (pt) polipeptídeos de haemophilus parasuis e métodos de uso
ECSP23024373A (es) Composición para inmunoterapia
BR112012024232A2 (pt) aptâmero para ngf e uso do mesmo.
BR112023002724A2 (pt) Neoantígenos ras e seus usos
AR051928A1 (es) Peptidos y derivados tipo apl de la hsp60 y composiciones farmaceuticas
BR112022001710A2 (pt) Moléculas mhc de classe ii e métodos de uso das mesmas
BR112022001704A2 (pt) Moléculas mhc de classe ii e métodos de uso das mesmas
BR112022001702A2 (pt) Moléculas mhc classe ii e métodos de uso das mesmas
MX2021010837A (es) Receptores en linfocitos t de la proteina 1 de tumor de wilms (wt1) de alta avidez.
BR112021012240A2 (pt) Terapia de gene-célula-tronco hematopoiética para síndrome wiskott-aldrich
BR0313083A (pt) moléculas de adamts4 modificadas,polinucleotìdeo, vetor, processos para produção, composição farmacêutica, bem como uso das mesmas
BR112022012057A2 (pt) Novos métodos de entrega celular
MX2022001204A (es) Métodos de identificación de receptores de linfocitos t.
BR112013013158B1 (pt) composições farmacêutica para uso no tratamento de câncer, métodos in vitro para induzir célula apresentadora de antígeno, bem como vetor, e uso